SRPT • US8036071004
Health CareThis investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders.
Sarepta Therapeutics shares jumped after the FDA issued a new boxed warning for Elevidys. read more
Sarepta Therapeutics Inc.’s controversial gene therapy for a rare muscle condition will remain available in the US with a strict new warning about potentially d...
read more
Enough though Sarepta shares are crashing, "Pharma Bro" Martin Shkreli says he still likes the stock. read more
These are some of the stocks posting the largest moves in the premarket.
Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare genetic diseases. The company's lead product is Exondys 51, a treatment for Duchenne muscular dystrophy (DMD). Sarepta Therapeutics...